ERLEADA® (apalutamide) Continued to Demonstrate Significant Improvement in Overall Survival for Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Analysis of the TITAN Study

June 14th 2021

Next-Generation Sequencing Minimal Residual Disease Testing in Blood Cancer Is Needed Now More Than Ever

June 9th 2021

Sponsored Content by Adaptive Biotechnologies

A Conversation about Somatic, Incidental Germline, and Standalone Germline Testing in Clinical Practice

June 7th 2021

Sponsored Content by Tempus

Advancing Care in Metastatic Breast Cancer

June 3rd 2021

Sponsored Content by SANOFI

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Offers Subcutaneous CD38-Directed Antibody to Health Care Providers and Their Multiple Myeloma Patients

April 26th 2021

Since the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.

Multi-stakeholder collaboration: the catalyst for innovation in kidney cancer care

March 31st 2021

Sponsored Content by Ipsen

Applying RxPONDER to Clinical Practice

March 30th 2021

Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.

More Can Be Done for Asian American Lung Cancer Patients

December 22nd 2020

Targeted Treatment Helps Delay ALK+ mNSCLC Progression

December 16th 2020

Remarkable progress has been made in the treatment of ALK+ mNSCLC patients, and the field continues to grow at a rapid pace.

Rethinking How We Approach Stage 3 Lung Cancer Treatment

October 20th 2020

As ongoing research continues to unlock the mechanisms of non–small cell lung cancer, it’s becoming increasingly clear that healthcare providers need to start rethinking how treatment is approached—especially for Stage 3 disease.